SHOULD BEYONDSPRING BE A PART OF YOUR PORTFOLIO?
Post# of 8
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company that has a major upcoming catalyst in the form of a PDUFA date of November 30, 2021 for its lead asset plinabulin in CIN prevention.
However getting an approval may not be a walk in the park for the Company!
Read on to find out more!